A Maltol-Containing Ruthenium Polypyridyl Complex as a Potential Anticancer Agent
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F20%3A00559789" target="_blank" >RIV/68378050:_____/20:00559789 - isvavai.cz</a>
Result on the web
<a href="https://chemistry-europe-onlinelibrary-wiley-com.d360prx.biomed.cas.cz/doi/10.1002/chem.201904877" target="_blank" >https://chemistry-europe-onlinelibrary-wiley-com.d360prx.biomed.cas.cz/doi/10.1002/chem.201904877</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/chem.201904877" target="_blank" >10.1002/chem.201904877</a>
Alternative languages
Result language
angličtina
Original language name
A Maltol-Containing Ruthenium Polypyridyl Complex as a Potential Anticancer Agent
Original language description
Cancer is one of the main causes of death worldwide. Chemotherapy, despite its severe side effects, is to date one of the leading strategies against cancer. Metal-based drugs present several potential advantages when compared to organic compounds and they have gained trust from the scientific community after the approval on the market of the drug cisplatin. Recently, we reported the ruthenium complex ([Ru(DIP)(2)(sq)](PF6) (where DIP is 4,7-diphenyl-1,10-phenantroline and sq is semiquinonate) with a remarkable potential as chemotherapeutic agent against cancer, both in vitro and in vivo. In this work, we analyse a structurally similar compound, namely [Ru(DIP)(2)(mal)](PF6), carrying the flavour-enhancing agent approved by the FDA, maltol (mal). To possess an FDA approved ligand is crucial for a complex, whose mechanism of action might include ligand exchange. Herein, we describe the synthesis and characterisation of [Ru(DIP)(2)(mal)](PF6), its stability in solutions and under conditions that resemble the physiological ones, and its in-depth biological investigation. Cytotoxicity tests on different cell lines in 2D model and on HeLa MultiCellular Tumour Spheroids (MCTS) demonstrated that our compound has higher activity than cisplatin, inspiring further tests. [Ru(DIP)(2)(mal)](PF6) was efficiently internalised by HeLa cells through a passive transport mechanism and severely affected the mitochondrial metabolism.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/GA17-02080S" target="_blank" >GA17-02080S: Study of molecular mechanisms involved in suppression of transcription-associated genomic instability</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Chemistry - A European Journal
ISSN
0947-6539
e-ISSN
1521-3765
Volume of the periodical
26
Issue of the periodical within the volume
22
Country of publishing house
DE - GERMANY
Number of pages
13
Pages from-to
4997-5009
UT code for WoS article
000521613900001
EID of the result in the Scopus database
—